<DOC>
	<DOCNO>NCT01773681</DOCNO>
	<brief_summary>The purpose study use magnetic resonance imaging ( MRI ) high-resolution peripheral quantitative compute tomography ( HR-pQCT ) techniques look damage disease activity progression hand wrist joint patient rheumatoid arthritis . The central hypothesis ongoing erosion cartilage loss rheumatoid arthritis due persistent inflammation , poorly detect clinical examination marker systemic inflammation .</brief_summary>
	<brief_title>Novel Imaging Markers Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Certolizumab Pegol</mesh_term>
	<criteria>The inclusion criterion patient enrol : RA 2010 ACR classification criterion Age ≥ 18 year enrollment Ability give consent follow study protocol Prednisone permit dos ≤10 mg daily Women reproductive potential must agree use acceptable method birth control treatment Additional inclusion criterion group I : DAS28 ≤ 3.2 last 2months prior baseline visit On MTX stable dose &gt; 8 week prior baseline visit No biologic therapy past 6months prior baseline visit No anticipate biologic therapy Additional inclusion criterion group II : DAS28 &gt; 3.2 No biologic therapy past 6months prior baseline visit Scheduled initiate antiTNF therapy use CIMZIA Exclusion Criteria patient enrol : Any psychiatric disorder prevents subject provide informed consent Inability unwillingness follow protocol Estimated glomerular filtration rate ( eGFR , calculate base serum creatinine ) &lt; 60 ml/min/1.72m2 Known allergy hypersensitivity study product ( include gadolinium ) History injury surgery wrist hand scan Inability place nondominant hand appropriately image History claustrophobia ; inability tolerate MRI contraindication MRI Pregnancy breastfeed Diabetes mellitus require insulin therapy Prednisone dose &gt; 10 mg/day ( equivalent dose another corticosteroid ) within 1 month baseline visit Any investigational agent within early 4 week 5 halflives prior randomization Any biologic therapy within 6month prior baseline visit Any condition treatment , opinion investigator , place subject unacceptable risk participant study Additional exclusion criterion Group II : Chronic persistent infection include limited human immunodeficiency virus [ HIV ] , hepatitis B , hepatitis C , listeriosis , TB , opportunistic infection ) Active infection severe infection require hospitalization treatment intravenous ( IV ) antibiotic , IV antiviral , IV antifungal within 30 day prior baseline visit , oral antibiotic , oral antiviral , oral antifungal within 14 day prior baseline visit Receipt live vaccine within 4 week prior baseline visit History malignancy within past 5 year treat localized carcinoma situ cervix adequately treat nonmetastatic squamous basal cell skin carcinoma</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>